{"id":167458,"date":"2024-02-01T14:31:34","date_gmt":"2024-02-01T13:31:34","guid":{"rendered":"https:\/\/www.bordeaux-neurocampus.fr\/un-espoir-de-therapie-genique-pour-traiter-lepilepsie-pharmacoresistante\/"},"modified":"2024-02-08T14:02:59","modified_gmt":"2024-02-08T13:02:59","slug":"un-espoir-de-therapie-genique-pour-traiter-lepilepsie-pharmacoresistante","status":"publish","type":"post","link":"https:\/\/www.bordeaux-neurocampus.fr\/en\/un-espoir-de-therapie-genique-pour-traiter-lepilepsie-pharmacoresistante\/","title":{"rendered":"Un espoir de th\u00e9rapie g\u00e9nique pour traiter l\u2019\u00e9pilepsie pharmacor\u00e9sistante"},"content":{"rendered":"<figure id=\"attachment_167455\" aria-describedby=\"caption-attachment-167455\" style=\"width: 360px\" class=\"wp-caption alignright\"><img loading=\"lazy\" decoding=\"async\" class=\"size-medium wp-image-167455\" src=\"https:\/\/www.bordeaux-neurocampus.fr\/wp-content\/uploads\/2024\/02\/mulle-hippocampe-vign-360x240.png\" alt=\"Section d\u2019hippocampe humain \u00a9 Christophe Mulle, Val\u00e9rie Cr\u00e9pel \" width=\"360\" height=\"240\" srcset=\"https:\/\/www.bordeaux-neurocampus.fr\/wp-content\/uploads\/2024\/02\/mulle-hippocampe-vign-360x240.png 360w, https:\/\/www.bordeaux-neurocampus.fr\/wp-content\/uploads\/2024\/02\/mulle-hippocampe-vign-136x91.png 136w, https:\/\/www.bordeaux-neurocampus.fr\/wp-content\/uploads\/2024\/02\/mulle-hippocampe-vign-640x426.png 640w, https:\/\/www.bordeaux-neurocampus.fr\/wp-content\/uploads\/2024\/02\/mulle-hippocampe-vign.png 720w\" sizes=\"auto, (max-width: 360px) 100vw, 360px\" \/><figcaption id=\"caption-attachment-167455\" class=\"wp-caption-text\">Section d\u2019hippocampe humain \u00a9 Christophe Mulle, Val\u00e9rie Cr\u00e9pel<\/figcaption><\/figure>\n<p class=\"\">L\u2019entreprise n\u00e9erlandaise uniQure a derni\u00e8rement annonc\u00e9 qu\u2019elle allait entamer les premiers essais cliniques d\u2019une th\u00e9rapie g\u00e9nique permettant de traiter l\u2019\u00e9pilepsie du lobe temporal. Une nouvelle approche qui pourrait venir en aide \u00e0 de nombreux patients affichant une r\u00e9sistance aux traitements m\u00e9dicamenteux.<\/p>\n<p>D\u2019apr\u00e8s <a href=\"https:\/\/www.fondation-epilepsie.fr\/\">la Fondation fran\u00e7aise pour la recherche sur l\u2019\u00e9pilepsie (FFRE)<\/a>, la maladie touche 650 000 personnes en France, la forme la plus fr\u00e9quente chez l\u2019adulte \u00e9tant l\u2019\u00e9pilepsie du lobe temporal. La plupart des patients sont trait\u00e9s au moyen de m\u00e9dicaments anti\u00e9pileptiques, qui s\u2019av\u00e8rent cependant inefficaces dans environ 30 % des cas (pharmacor\u00e9sistance). \u00c0 l\u2019heure actuelle, la seule solution consiste alors \u00e0 r\u00e9aliser une intervention chirurgicale (r\u00e9section) pour retirer la partie du cerveau \u00e0 l\u2019origine des crises \u2013 incluant g\u00e9n\u00e9ralement l\u2019hippocampe, situ\u00e9 dans le lobe temporal. Une m\u00e9thode souvent efficace, mais invasive et susceptible d\u2019alt\u00e9rer des fonctions cognitives telles que la m\u00e9moire ou l\u2019orientation dans l\u2019espace.<\/p>\n<p><strong>Christophe Mulle<\/strong>, directeur de recherche au CNRS, responsable d&#8217;\u00e9quipe \u00e0 l&#8217;IINS, et Val\u00e9rie Cr\u00e9pel, directrice de recherche \u00e0 l\u2019Inserm, ont explor\u00e9 une autre voie possible de traitement, \u00e0 travers un projet collaboratif amorc\u00e9 en 2011. \u00c0 l\u2019inverse des approches traditionnelles, leur id\u00e9e \u00e9tait de s\u2019attaquer \u00e0 une cible th\u00e9rapeutique sp\u00e9cifique, situ\u00e9e au sein de l\u2019hippocampe. Son nom : les r\u00e9cepteurs ka\u00efnate.<\/p>\n<h3>Lire la suite<\/h3>\n<p><a href=\"https:\/\/www.cnrsinnovation.com\/actualite\/un-espoir-de-therapie-genique-pour-traiter-lepilepsie-pharmacoresistante\/\">Article sur www.cnrsinnovation.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Source : CNRS Innovation. D&#8217;apr\u00e8s les travaux de Christophe Mulle (IINS) <\/p>\n","protected":false},"author":108,"featured_media":167456,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[140,443],"tags":[],"class_list":["post-167458","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-for-all","category-innovation-en"],"_links":{"self":[{"href":"https:\/\/www.bordeaux-neurocampus.fr\/en\/wp-json\/wp\/v2\/posts\/167458","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bordeaux-neurocampus.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bordeaux-neurocampus.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bordeaux-neurocampus.fr\/en\/wp-json\/wp\/v2\/users\/108"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bordeaux-neurocampus.fr\/en\/wp-json\/wp\/v2\/comments?post=167458"}],"version-history":[{"count":3,"href":"https:\/\/www.bordeaux-neurocampus.fr\/en\/wp-json\/wp\/v2\/posts\/167458\/revisions"}],"predecessor-version":[{"id":167476,"href":"https:\/\/www.bordeaux-neurocampus.fr\/en\/wp-json\/wp\/v2\/posts\/167458\/revisions\/167476"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.bordeaux-neurocampus.fr\/en\/wp-json\/wp\/v2\/media\/167456"}],"wp:attachment":[{"href":"https:\/\/www.bordeaux-neurocampus.fr\/en\/wp-json\/wp\/v2\/media?parent=167458"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bordeaux-neurocampus.fr\/en\/wp-json\/wp\/v2\/categories?post=167458"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bordeaux-neurocampus.fr\/en\/wp-json\/wp\/v2\/tags?post=167458"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}